{"id":18426,"date":"2018-02-27T10:25:20","date_gmt":"2018-02-27T15:25:20","guid":{"rendered":"https:\/\/www.terrybryant.com\/?p=18426"},"modified":"2024-02-27T06:17:53","modified_gmt":"2024-02-27T12:17:53","slug":"leukemia-drug-tasigna-linked-artery-disease-2","status":"publish","type":"post","link":"https:\/\/www.terrybryant.com\/tasigna-artery-disease","title":{"rendered":"Leukemia Drug Tasigna Linked to Artery Disease"},"content":{"rendered":"

If you or someone you care about is being\u00a0or has been treated with the leukemia drug\u00a0Tasigna\u00ae\u00a0from drug manufacturer Novartis, you’ll want to be aware that the drug is the subject of lawsuits and claims across the country. The drug was popularly prescribed in the treatment of a certain type of leukemia and has recently been linked to artery disease and atherosclerosis.<\/p>

<\/div>\n

Types of Leukemia<\/h2>\n

Leukemia is often referred to as cancer of the blood\u00a0and is categorized in two broad types, acute and chronic. Acute leukemia is very invasive and spreads quickly. Chronic leukemia is a slower-growing form of the disease.<\/p>\n

Acute forms of leukemia include Acute\u00a0Lymphocytic\u00a0Leukemia (ALL) and Acute Myeloid Leukemia (AML). Almost all childhood leukemia cases are either ALL or AML.<\/p>\n

Chronic forms of leukemia include Chronic\u00a0Lymphocytic\u00a0Leukemia (CLL), Chronic Myeloid Leukemia (CML), and Chronic\u00a0Myelomonocytic\u00a0Leukemia (CMML).<\/p>\n

The\u00a0American Cancer Society<\/a>\u00a0states that leukemia is a cancer of early blood-forming cells. While it most frequently affects white blood cells, it has also been known to start in other types of blood cells.\u00a0Treatments can vary according to the severity of the leukemia involved. For patients with what is known as Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), the drug\u00a0Tasigna produced by Novartis was frequently prescribed.<\/p>\n

The intent of the drug was to slow down the spread of the disease by inhibiting the growth of cancerous cells. Unfortunately, it has had some unintended tragic consequences.<\/p>\n

Tasigna’s\u00a0Effects on the Arteries<\/h2>\n

When\u00a0Tasigna\u00a0was first approved by the FDA in 2007, like many drugs it came with a long list of precautions. Now, it is being linked to a range of serious health issues, including atherosclerosis. The results of atherosclerosis can include:<\/strong><\/p>\n